Evotec stock gains 2.45 percent as chief scientist exits

Published on 09/29/2026 at 11:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock trades at EUR 2.93 on September 29, 2026, after a leadership change. H1 revenue fell 19.2 percent to EUR 300.1 million and adjusted EBITDA reached a EUR 42.7 million loss.

Fotorealistisches Pharma-Labor mit Wissenschaftlern bei Wirkstoffscreening in moderner Biotech-Anlage — Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec stock gained 2.45 percent to EUR 2.93 at Lang & Schwarz on September 29, 2026 at 11:11 a.m. CEST, versus the Xetra close of EUR 2.86 on September 28, 2026. The move followed the company announcement that Chief Scientific Officer Cord Dohrmann will leave his post on September 30, 2026, while Evotec searches for a successor, as EQS News reported on September 29, 2026.

Leadership change meets weak results

Dohrmann has served as Evotec's chief scientific officer and a member of the management board since 2010. The transition adds a management issue to an operating picture shaped by weaker revenue conversion and delayed partnership contributions.

For the first half of 2026, group revenue fell 19.2 percent year over year to EUR 300.1 million. Adjusted Group EBITDA deteriorated from a EUR 1.9 million loss in the first half of 2025 to a EUR 42.7 million loss in the first half of 2026, according to Nadir Alpha.

Guidance sets the financial hurdle

Evotec's 2026 guidance calls for revenue of EUR 570 million to EUR 610 million, down from the earlier EUR 700 million to EUR 780 million range. Adjusted EBITDA is now expected to be a loss of EUR 70 million to EUR 105 million, compared with the previous range of EUR 0 million to EUR 40 million, according to Nadir Alpha.

The comparison matters because the revised outlook combines lower sales with a swing from potential adjusted EBITDA profit to a substantial loss. That leaves execution of the Horizon transformation program and the timing of new partnerships as central financial markers for the stock.

Berenberg keeps a cautious target

Berenberg maintained its Hold rating and EUR 3.60 price target after a discussion with Chief Executive Officer Christian Wojczewski, as Wallstreet Online reported on September 25, 2026. Against the EUR 2.93 Lang & Schwarz price, the target lies 22.87 percent above the reference price, while the unchanged rating signals that the recovery case still depends on measurable operating progress.

Evotec stock gains 2.45 percent

Evotec stock was trading at EUR 2.93 at Lang & Schwarz on September 29, 2026 at 11:11 a.m. CEST, up 2.45 percent versus the Xetra close of EUR 2.86 on September 28, 2026. The market capitalization stood at EUR 499.0 million as of September 28, 2026.